Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi 830011, Xinjiang, China.
State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
EBioMedicine. 2020 Jul;57:102831. doi: 10.1016/j.ebiom.2020.102831. Epub 2020 Jun 21.
Oesophageal squamous cell carcinoma (ESCC) is a highly heterogeneous cancer with a distinct incidence and prognosis. Molecular events driving ESCC subtypes and prognosis have not been established, and little is known regarding Chinese ESCC patients in Xinjiang, China.
Here, we first integrated the genomic and transcriptomic data of 125 Chinese ESCC patients from Xinjiang Tumor Hospital (Urumqi, China). Two independent datasets of GSE53624 and The Cancer Genome Atlas (TCGA) ESCC were used to confirm the results of this study. DNA mutation and overall survival (OS) were analysed independently in the Chinese ESCC cohorts.
Genomic analyses revealed a consistent mutation signatures and discordance among mutated genes across the different ESCC cohorts. In addition, transcriptomic profiling identified three Chinese ESCC subtypes associated with clinical and molecular attributes, including patient survival, lymph node status and genetic profile. Moreover, Chinese ESCC subtypes have distinct metabolic, inflammatory, metastatic, and cell proliferation features and unique potential therapeutics. Furthermore, the expression of cell cycle- and/or cell proliferation-related genes was higher in cyclin D1 (CCND1)-amplified tumours than in CCND1-normal tumours from Chinese ESCC patients, suggesting that CCND1 amplification promoted cell proliferation.
Our findings provide a framework to facilitate the rational categorization of ESCC in Chinese patients and a foundation for new therapies.
This study was supported by the Research Fund of Key Laboratory of Xinjiang oncology (Grant no.2017D04006) and the Outstanding Youth Science and technology training project fund of Xinjiang, China (Grant no. 2017Q058).
食管鳞状细胞癌(ESCC)是一种高度异质性的癌症,具有明显的发病率和预后。驱动 ESCC 亚型和预后的分子事件尚未确定,对于中国新疆的 ESCC 患者知之甚少。
我们首先整合了来自中国新疆肿瘤医院(乌鲁木齐)的 125 名中国 ESCC 患者的基因组和转录组数据。使用两个独立的数据集 GSE53624 和癌症基因组图谱(TCGA)ESCC 来验证本研究的结果。在中国 ESCC 队列中独立分析 DNA 突变和总生存期(OS)。
基因组分析显示,不同 ESCC 队列之间一致的突变特征和突变基因的不一致性。此外,转录组谱分析确定了三种与临床和分子特征相关的中国 ESCC 亚型,包括患者生存、淋巴结状态和遗传特征。此外,中国 ESCC 亚型具有不同的代谢、炎症、转移和细胞增殖特征,以及独特的潜在治疗方法。此外,与细胞周期和/或细胞增殖相关的基因在 cyclin D1(CCND1)扩增的肿瘤中的表达高于 CCND1 正常肿瘤,这表明 CCND1 扩增促进了细胞增殖。
我们的研究结果为中国患者 ESCC 的合理分类提供了框架,并为新疗法奠定了基础。
本研究得到了新疆肿瘤重点实验室研究基金(No.2017D04006)和中国新疆优秀青年科技人才培养项目基金(No.2017Q058)的支持。